Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects

Hypertension

Volumn 43, Issue 5, 2004, Pages 963-969

  Verdecchia, Paolo ^a   Reboldi, Gianpaolo ^a   Angeli, Fabio ^a   Borgioni, Claudia ^a   Gattobigio, Roberto ^b   Filippucci, Lucia ^a   Norgiolini, Silvia ^a   Bracco, Costanza ^a   Porcellati, Carlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ospedale Beato G Villa   (Italy)

Author keywords

Blood pressure; Diuretics; Echocardiography; Epidemiology; Hypertension; Hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; DIURETICS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LIFE TABLES; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; SMOKING;

EID: 2342652390     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000125726.92964.ab     Document Type: Article

References (36)

1. Am Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-S82.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care. 2003;26:3160-3167.
3. Gerber LM, Madhavan S, Alderman MH. Coincident hypertension: deleterious effects on patients with hyperglycemia. N Y State J Med. 1983;83:693-696.
4. Pell S, D'Alonzo CA. Some aspects of hypertension in diabetes mellitus. JAMA. 1967;202:104-110.
5. Jarrett RJ, McCartney P, Keen H. The Bedford Survey: 10-year mortality rates in newly diagnosed diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-84.
6. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1992;118:273-278.
7. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet. 1976;1:564-566.
8. Furman BL. Impairment of glucose tolerance produced by diuretics and other drugs. Pharmacol Ther. 1981;12:613-649.
9. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
10. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindhohn LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular mortality and morbidity in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
11. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
13. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;26:1802-1807.
14. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci C, Santucci A, Reboldi P. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
15. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
16. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-719.
17. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C. Prognostic validation of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol. 1998;31:383-390.
18. Verdecchia P, Schillaci G, Boldrini F, Porcellati C. Quantitative assessment of day-to-day spontaneous variability in non-invasive ambulatory blood pressure measurements in essential hypertension. J Hypertens. 1991;9:S322-S323.
19. Am Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
20. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972;34:187-220.
21. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33:1130-1134.
22. Sowers JR, Epstain M, Frohlich ED. Diabetes, hypertension and cardiovascular disease. An update. Hypertension. 2001;37:1053-1059.
23. Samuelsson O, Pennert K, Andersson O, Berglund G, Hedner T, Persson B, Wedel H, Wilhelmsen L. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension-are they of prognostic importance? Observational study. BMJ. 1996;313:660-663.
24. World Health Organization Expert Committee on Diabetes Mellitus. Second Report. Geneva: WHO, 1980. (Technical Report Series, No 646).
25. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ. 2003;326:681.
26. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
27. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
28. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr., Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
29. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
30. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A; Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003;12:160-167.
31. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
32. Ramsay LE, Yeo WW, Jackson PR. Diabetes, impaired glucose tolerance and insulin resistance with diuretics. Eur Heart J. 1992;13:68-71.
33. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella El EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2572.
34. Von Eckardstein A, Schulte H, Assmarm G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the Am Diabetes Association. J Clin Endocrinol Metab. 2000;85:3101-3108.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
36. Henry P, Thomas F, Benetos A, Guize L. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension. 2002;40:458-463.